- Home
- RNXT vs AKTX Comparison
RNXT vs AKTX Comparison
Compare RNXT & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- AKTX
- Stock Information
- Founded
- RNXT 2012
- AKTX N/A
- Country
- RNXT United States
- AKTX United States
- Employees
- RNXT N/A
- AKTX N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- RNXT Health Care
- AKTX Health Care
- Exchange
- RNXT Nasdaq
- AKTX Nasdaq
- Market Cap
- RNXT 44.6M
- AKTX 41.8M
- IPO Year
- RNXT 2021
- AKTX N/A
- Fundamental
- Price
- RNXT $1.36
- AKTX $1.17
- Analyst Decision
- RNXT Strong Buy
- AKTX
- Analyst Count
- RNXT 2
- AKTX 0
- Target Price
- RNXT $7.25
- AKTX N/A
- AVG Volume (30 Days)
- RNXT 147.2K
- AKTX 27.5K
- Earning Date
- RNXT 08-12-2025
- AKTX 08-18-2025
- Dividend Yield
- RNXT N/A
- AKTX N/A
- EPS Growth
- RNXT N/A
- AKTX N/A
- EPS
- RNXT N/A
- AKTX N/A
- Revenue
- RNXT $240,000.00
- AKTX N/A
- Revenue This Year
- RNXT $3,186.05
- AKTX N/A
- Revenue Next Year
- RNXT $291.93
- AKTX N/A
- P/E Ratio
- RNXT N/A
- AKTX N/A
- Revenue Growth
- RNXT N/A
- AKTX N/A
- 52 Week Low
- RNXT $0.75
- AKTX $0.85
- 52 Week High
- RNXT $1.69
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- RNXT 55.76
- AKTX 45.49
- Support Level
- RNXT $1.27
- AKTX $1.10
- Resistance Level
- RNXT $1.42
- AKTX $1.18
- Average True Range (ATR)
- RNXT 0.07
- AKTX 0.07
- MACD
- RNXT -0.02
- AKTX 0.00
- Stochastic Oscillator
- RNXT 62.50
- AKTX 53.25
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.